Generic Name and Formulations:
Erythromycin 3%, benzoyl peroxide 5%; gel.
Cutanea Life Sciences, Inc.
Indications for AKTIPAK:
Contents must be mixed (in the palm of the hand) prior to use. Apply to cleansed, dried areas twice daily.
Avoid eyes, mouth, mucous membranes. Discontinue if excessive irritation occurs. Avoid excessive or prolonged exposure to sunlight. Flammable. Pregnancy (Cat.C). Nursing mothers.
Additive irritation with peeling, desquamating, abrasive agents. Concomitant other topical acne products: not recommended.
Macrolide antibiotic + antibacterial/ keratolytic.
Dry skin, application site reactions (eg, stinging, erythema, burning), blepharitis, pruritus, photosensitivity, peeling, superinfection; may bleach hair or fabrics.
Gel (dual-chamber pouches, mixed by patient)—60
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|